Free Trial

CVS Health (CVS) Stock Forecast & Price Target

CVS Health logo
$56.46
+0.07 (+0.12%)
(As of 05:32 PM ET)

CVS Health - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
8
Buy
13

Based on 21 Wall Street analysts who have issued ratings for CVS Health in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 21 analysts, 8 have given a hold rating, and 13 have given a buy rating for CVS.

Consensus Price Target

$74.58
32.09% Upside
According to the 21 analysts' twelve-month price targets for CVS Health, the average price target is $74.58. The highest price target for CVS is $100.00, while the lowest price target for CVS is $60.00. The average price target represents a forecasted upside of 32.09% from the current price of $56.46.
Get the Latest News and Ratings for CVS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for CVS Health and its competitors.

Sign Up

CVS Analyst Ratings Over Time

TypeCurrent Forecast
11/1/23 to 10/31/24
1 Month Ago
10/2/23 to 10/1/24
3 Months Ago
8/3/23 to 8/2/24
1 Year Ago
11/1/22 to 11/1/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
13 Buy rating(s)
11 Buy rating(s)
13 Buy rating(s)
14 Buy rating(s)
Hold
8 Hold rating(s)
10 Hold rating(s)
10 Hold rating(s)
3 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$74.58$72.10$75.05$94.56
Forecasted Upside32.09% Upside17.16% Upside26.53% Upside37.56% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

CVS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CVS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

CVS Health Stock vs. The Competition

TypeCVS HealthRetail/Wholesale CompaniesS&P 500
Consensus Rating Score
2.62
2.50
2.50
Consensus RatingModerate BuyHoldHold
Predicted Upside33.11% Upside38.32% Upside9.97% Upside
News Sentiment Rating
Neutral News

See Recent CVS News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
10/24/2024Mizuho
2 of 5 stars
 Lower TargetOutperform ➝ Outperform$73.00 ➝ $66.00+16.24%
10/23/2024Barclays
3 of 5 stars
A. Mok
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOverweight ➝ Overweight$82.00 ➝ $75.00+31.93%
10/11/2024Truist Financial
2 of 5 stars
 Boost TargetBuy ➝ Buy$66.00 ➝ $76.00+13.43%
10/8/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$62.00 ➝ $75.00+14.26%
10/4/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
C. Rhyee
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$59.00 ➝ $85.00+35.09%
10/1/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$62.00 ➝ $62.00+0.27%
9/4/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$68.00 ➝ $68.00+17.22%
8/12/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight ➝ Equal Weight$60.00 ➝ $61.00+8.04%
8/9/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetHold ➝ Hold$64.00 ➝ $63.00+10.24%
5/30/2024Baird R W
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Ha
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
5/30/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$101.00 ➝ $86.00+53.54%
5/30/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageNeutral$61.00+13.55%
5/8/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
C. Graja
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetBuy ➝ Buy$100.00 ➝ $80.00+44.85%
5/2/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$95.00 ➝ $77.00+41.73%
5/2/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$85.00 ➝ $74.00+36.08%
5/2/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral$85.00 ➝ $60.00+6.53%
5/1/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Cherny
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
5/1/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Market Perform$87.00 ➝ $60.00+5.60%
3/15/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$93.00 ➝ $94.00+21.75%
12/22/2023HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$94.00+19.56%
11/2/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$110.00 ➝ $100.00+43.55%
10/10/2023Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$93.00 ➝ $80.00+11.41%
9/12/2023Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradePeer Perform ➝ Outperform$80.00+16.36%
8/17/2023Edward Jones
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
8/4/2023Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$90.00 ➝ $85.00+14.34%
5/8/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$125.00 ➝ $96.00+35.82%
2/9/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$130.00 ➝ $143.00+60.75%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 07:47 PM ET.


Should I Buy CVS Health Stock? CVS Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, October 21, 2024. Please send any questions or comments about these CVS Health pros and cons to contact@marketbeat.com.

CVS Health
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in CVS Health Co.:

  • CVS Health Co. has a dividend yield of 4.58%, providing investors with a steady income stream. A higher dividend yield can be attractive to income-seeking investors.
  • Recent stock performance shows CVS Health Co. trading at $64.59, indicating a potential for capital appreciation. A rising stock price can lead to capital gains for investors.
  • CVS Health Co. reported a return on equity of 12.72%, showcasing the company's ability to generate profit from shareholders' equity. A higher return on equity is generally favorable for investors.
  • Analysts expect CVS Health Co. to post 6.51 EPS for the current fiscal year, indicating potential earnings growth. Higher earnings per share can positively impact stock prices and investor returns.
  • CVS Health Co. operates through various segments, including Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness, diversifying its revenue streams and potentially reducing risk for investors.

CVS Health
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in CVS Health Co. for these reasons:

  • CVS Health Co. has a debt-to-equity ratio of 0.83, indicating a significant level of debt compared to equity. High debt levels can pose financial risks and impact the company's financial stability.
  • The company's stock price has experienced fluctuations, with a 52-week high of $83.25 and a 52-week low of $52.77. Volatility in stock prices can lead to uncertainty for investors.
  • CVS Health Co. has a beta of 0.54, suggesting lower volatility compared to the market. While lower volatility can be perceived as less risky, it may also limit potential returns for investors seeking higher-risk investments.
  • The company's revenue growth was modest at 2.6% compared to the same quarter last year. Slower revenue growth rates may indicate challenges in expanding the business and could impact future stock performance.
  • Despite a consensus rating of "Moderate Buy," there have been mixed analyst opinions on CVS Health Co., with some recommending a hold rating. Differing analyst views may lead to uncertainty among investors regarding the company's future prospects.

CVS Forecast - Frequently Asked Questions

According to the research reports of 21 Wall Street equities research analysts, the average twelve-month stock price forecast for CVS Health is $74.58, with a high forecast of $100.00 and a low forecast of $60.00.

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CVS Health in the last year. There are currently 8 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CVS shares.

According to analysts, CVS Health's stock has a predicted upside of 32.09% based on their 12-month stock forecasts.

Over the previous 90 days, CVS Health's stock had 2 upgrades by analysts.

Analysts like CVS Health more than other "retail/wholesale" companies. The consensus rating for CVS Health is Moderate Buy while the average consensus rating for "retail/wholesale" companies is Hold. Learn more on how CVS compares to other companies.


This page (NYSE:CVS) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners